Case Study: Boehringer Ingelheim Pharmaceuticals, Inc. in partnership with the National Stroke Association


Atrial fibrillation, also known as AFib, is an irregular sustained heartbeat caused by a quivering of the upper chambers of the heart, called the atria. It is the most common serious heart arrhythmia, and affects more than 2.3 million people nationwide. The most serious complication of AFib is stroke. In fact, AFib patients are nearly five times more likely to suffer a stroke than those without the condition. Less than 40% of patients take the initiative to ask their HCP, about their personal risk of stroke or stroke prevention treatment


AFib is constantly working to promote awareness and reach the patients with information.

With the support of healthcare professionals and family and friends, people with AFib can strive to maximize their health. Generating awareness is the key to helping patients understand the conditions and the goal is to offer tips, discussions and insights about how to collaborate with healthcare professionals to help reduce the risk of AFib-related stroke.


Two years in a row we initiated a live webcast which reaches hundreds of patients and patient advocates. The webcast enabled us to bring together leading experts in the field of AFib, as well as a patient who has graciously agreed to share some of her own personal experiences, all while we unveil compelling new survey findings. The webcast reach more then 500 participants.



Boehringer Ingelheim Pharmaceuticals

National Stroke Association